Hematological alterations in lepromatous leprosy: A cross-sectional observational study.
Adult
Case-Control Studies
Cross-Sectional Studies
Dapsone
/ administration & dosage
Erythrocyte Indices
/ drug effects
Female
Hematocrit
/ statistics & numerical data
Hematologic Diseases
/ chemically induced
Hemoglobins
/ drug effects
Hemolysis
Humans
Incidence
India
/ epidemiology
Leprostatic Agents
/ administration & dosage
Leprosy, Lepromatous
/ blood
Male
Mean Platelet Volume
/ statistics & numerical data
Middle Aged
Platelet Count
/ statistics & numerical data
Severity of Illness Index
Cross-sectional
Dapsone
Hemolysis
Leprosy
Platelet count
Journal
Disease-a-month : DM
ISSN: 1557-8194
Titre abrégé: Dis Mon
Pays: United States
ID NLM: 0370657
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
pubmed:
5
12
2019
medline:
11
6
2020
entrez:
5
12
2019
Statut:
ppublish
Résumé
Dapsone has been the mainstay for the treatment of leprosy since its discovery in the 1940s. However, hematological disturbances are not uncommon in leprosy patients on daily dapsone therapy. Hence, the present study was conducted to document the hematologic alterations observed in lepromatous leprosy patients treated with Dapsone 100 mg daily. A cross-sectional observational study was conducted amongst 32 lepromatous leprosy patients treated with Dapsone 100 mg daily. A complete hemogram was conducted for all the study recruits. The test results were compared against the standard average values for adults for the given variables. The one sample t-test was employed to compare the difference between the study values and the standard normal values for adults. The statistical significance was considered at p < 0.05. The study reveals a marked decrease in hemoglobin concentration in patients on dapsone, 100 mg daily. Other hematological alterations found were reduced platelet count, reduced mean platelet volume, reduced Hematocrit, reduced Mean Corpuscular hemoglobin, reduced Mean Corpuscular hemoglobin concentration. (p < 0.05). Treatment of lepromatous leprosy with 100 mg daily Dapsone therapy may lead to hematological alterations. These findings are suggestive of dapsone-induced hemolysis.
Sections du résumé
BACKGROUND
BACKGROUND
Dapsone has been the mainstay for the treatment of leprosy since its discovery in the 1940s. However, hematological disturbances are not uncommon in leprosy patients on daily dapsone therapy. Hence, the present study was conducted to document the hematologic alterations observed in lepromatous leprosy patients treated with Dapsone 100 mg daily.
METHODOLOGY
METHODS
A cross-sectional observational study was conducted amongst 32 lepromatous leprosy patients treated with Dapsone 100 mg daily. A complete hemogram was conducted for all the study recruits. The test results were compared against the standard average values for adults for the given variables. The one sample t-test was employed to compare the difference between the study values and the standard normal values for adults. The statistical significance was considered at p < 0.05.
RESULTS
RESULTS
The study reveals a marked decrease in hemoglobin concentration in patients on dapsone, 100 mg daily. Other hematological alterations found were reduced platelet count, reduced mean platelet volume, reduced Hematocrit, reduced Mean Corpuscular hemoglobin, reduced Mean Corpuscular hemoglobin concentration. (p < 0.05).
CONCLUSION
CONCLUSIONS
Treatment of lepromatous leprosy with 100 mg daily Dapsone therapy may lead to hematological alterations. These findings are suggestive of dapsone-induced hemolysis.
Identifiants
pubmed: 31796205
pii: S0011-5029(19)30160-9
doi: 10.1016/j.disamonth.2019.100919
pii:
doi:
Substances chimiques
Hemoglobins
0
Leprostatic Agents
0
Dapsone
8W5C518302
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
100919Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None declared.